Healthcare Quarterly, 29(2) July 2026: 29-36.doi:10.12927/hcq.2026.27906
Advancing Canadian Research and Development
Addressing Canada’s Pharmaceutical Research and Development Intensity Gap: The Role of Health Data Transformation
Thomas Mullie and Anderson Chuck
Abstract
The life sciences industry, and specifically the pharmaceutical sub-sector, is a major funder of private sector research and development. Canada's life sciences industry reinvests less of its revenues in research and development (R&D) activities than those in peer countries, which hinders innovation, creates supply risks and contributes to Canada's poor productivity growth. Traditional approaches to incentivizing reinvestment, including tax incentives, direct funding and public research spending, have failed. As an alternative, transforming Canada's health data systems would enable faster and more comprehensive secondary use, making R&D investments safer and more productive. Our peers are already pursuing this strategy, meaning Canada risks being left behind unless we act.
This article is for subscribers only.
To view the entire article, sign in if you are a subscriber. Or select one of the options below.
Personal Subscriber? Sign In
Please note: To register for an event you must sign-in as an individual or create a personal Longwood's account. Thank you.
Comments
Be the first to comment on this!
You must sign in to comment Sign In or Create an Account to add comments
Related Content
Healthcare Quarterly
How to Recruit a High-Performing Hospital Board
HealthcarePapers
Professional Healthcare Regulation and Practice: The Case of Medicine in Britain
HealthcarePapers
Using Trends to Inform Regulatory Practices





